NEW YORK, NY, September 20, 2011 --- Enzo Biochem Inc. (NYSE:ENZ), announced today that it has added an independent regional sales office in Lyon, France to more directly service its customers in France. Previously, Enzo Life Sciences sold its products in France through a third party distributor.
The new office, opened on September 1, 2011 is staffed with an experienced team that has been servicing the Enzo Life Sciences’ customers for many years. This office will complement our existing global team that includes our European logistics center located in Lausen, Switzerland, as well as, our global Enzo Life Sciences headquarter located in Farmingdale, NY. Adding this local office, situated near the growing biotech cluster in Lyon will enable Enzo Life Sciences’ ability to provide next day delivery and immediate response to customer enquiries.
According to Andrew Whiteley, COO of Enzo Life Sciences, “Creation of an Enzo Life Sciences regional sales office will enable us to streamline the ordering process of ELS products within this important country” Our customers will be able to easily connect with us allowing for servicing of their needs directly.” “Removing one layer creates a direct connection between us and our customers. Our goal is to enable 24 shipping on orders placed and immediate responses to inquiries.”
The Branch Office Lyon is led by and under the responsibility of Christophe Bertrand. The contact details of the Branch Office Lyon are the following:
Enzo Life Sciences (ELS) AG
Branch Office Lyon
13, avenue Albert Einstein
F-69100 Villeurbanne
Tel: +33 472 440 655
Fax: +33 437 484 239
For further information, contact Christophe Bertrand, +33 472 440 655.
About Enzo Biochem
Enzo Biochem, Inc., is a growth-oriented integrated life sciences and biotechnology company focused on harnessing biological process to develop research tools, diagnostics and therapeutics, and serves as a provider of test services, including exotic tests, to the medical community. Since our founding in 1976, our strategic focus has been on the development of enabling technologies in the life sciences field. Enzo Life Sciences develops, produces and markets proprietary labeling and detection products for gene sequencing, genetic analysis and immunological research, among others. Its catalog of over 30,000 products serves the molecular biology, drug discovery and pathology research markets worldwide. Enzo Clinical Labs provides laboratory services for a growing roster of physicians in the New York Metropolitan area, Pennsylvania and New Jersey. Its tests include, in addition to routine tests, capabilities for detecting molecular infection disease, molecular oncology, autoimmune disorders and genetics. Enzo Clinical Labs also provides clinical diagnostic services that allow Enzo to capitalize on its extensive advanced molecular and cytogenetic capabilities and the broader trends in predictive and personalized diagnostics. Enzo Therapeutics is a biopharmaceutical venture that has developed multiple novel approaches in the areas of gastrointestinal, infectious, ophthalmic and metabolic diseases. It has focused its efforts on developing treatment regimens for diseases and conditions for which current treatment options are ineffective, costly, and/or cause unwanted side effects. In the course of the company’s research and development activities, Enzo has also developed a substantial portfolio of intellectual property asset with patent coverage across a number of key technologies.
Except for historical information, the matters discussed in this news release may be considered "forward-looking" statements within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended. Such statements include declarations regarding the intent, belief or current expectations of the Company and its management. Investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve a number of risks and uncertainties that could materially affect actual results. The Company disclaims any obligations to update any forward-looking statement as a result of developments occurring after the date of this press release.
